Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine.

ABSTRACT: Marburg virus (MARV) has been associated with sporadic episodes of hemorrhagic fever, including a recent highly publicized outbreak in Angola that produced severe disease and significant mortality in infected patients. MARV is also considered to have potential as a biological weapon. Recently, we reported the development of a promising attenuated, replication-competent vaccine against MARV based on recombinant vesicular stomatitis virus (VSV) expressing the glycoprotein of the Musoke strain of MARV (VSVDeltaG/MARVGP-Musoke). We used this vaccine to demonstrate complete protection of cynomolgus monkeys against a homologous MARV challenge. While these results are highly encouraging, an effective vaccine would need to confer protection against all relevant strains of MARV. Here, we evaluated

SUBMITTER: Daddario-DiCaprio KM 

PROVIDER: S-EPMC1617222 | biostudies-literature | 2006 Oct

REPOSITORIES: biostudies-literature